IMUXImmunic, Inc.

$138M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$20M

Net Income

-$21M

EPS (Diluted)

$-0.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$121M

Total Liabilities

$12M

Stockholders' Equity

$109M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$20M	-$18M	-9.4%
Net Income	-$21M	-$19M	-10.0%

IMUX Q3 2022 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena